EGFR and B-cell non-Hodgkin lymphoma: Numerous pre-clinical studies conducted in CD89 transgenic mice confirmed its superior ability to induce neutrophil-dependent tumor cell killing for different tumor-associated antigens, such as HER2/neu (on breast carcinoma), EpCAM (colon carcinoma), EGFR (epithelial carcinoma and renal cell carcinoma), HLA class II (B-cell lymphoma), CD30 (T- and B-cell lymphoma), and CD20 (B-cell lymphoma) (205).